PBYI
Puma Biotechnology Inc
NASDAQ · Biotechnology
$6.94
+0.15 (+2.21%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 46.64M | 42.11M | 46.96M |
| Net Income | 10.01M | 7.89M | 10.24M |
| EPS | — | — | — |
| Profit Margin | 21.5% | 18.7% | 21.8% |
| Rev Growth | +7.5% | +7.6% | -6.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 117.10M | 115.20M | 98.43M |
| Total Equity | 268.29M | 249.14M | 242.47M |
| D/E Ratio | 0.44 | 0.46 | 0.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 15.43M | 13.15M | 15.14M |
| Free Cash Flow | 4.56M | 4.76M | 6.11M |